- Home
- TENB vs VKTX Comparison
TENB vs VKTX Comparison
Compare TENB & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENB
- VKTX
- Stock Information
- Founded
- TENB 2002
- VKTX 2012
- Country
- TENB United States
- VKTX United States
- Employees
- TENB N/A
- VKTX N/A
- Industry
- TENB Computer Software: Prepackaged Software
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TENB Technology
- VKTX Health Care
- Exchange
- TENB Nasdaq
- VKTX Nasdaq
- Market Cap
- TENB 4.1B
- VKTX 3.5B
- IPO Year
- TENB 2018
- VKTX 2015
- Fundamental
- Price
- TENB $31.04
- VKTX $33.81
- Analyst Decision
- TENB Buy
- VKTX Strong Buy
- Analyst Count
- TENB 20
- VKTX 13
- Target Price
- TENB $42.63
- VKTX $86.92
- AVG Volume (30 Days)
- TENB 1.5M
- VKTX 4.0M
- Earning Date
- TENB 07-30-2025
- VKTX 07-23-2025
- Dividend Yield
- TENB N/A
- VKTX N/A
- EPS Growth
- TENB N/A
- VKTX N/A
- EPS
- TENB N/A
- VKTX N/A
- Revenue
- TENB $949,251,000.00
- VKTX N/A
- Revenue This Year
- TENB $10.62
- VKTX N/A
- Revenue Next Year
- TENB $7.88
- VKTX $338.60
- P/E Ratio
- TENB N/A
- VKTX N/A
- Revenue Growth
- TENB 11.41
- VKTX N/A
- 52 Week Low
- TENB $28.75
- VKTX $18.92
- 52 Week High
- TENB $45.45
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- TENB 35.88
- VKTX 58.37
- Support Level
- TENB $32.83
- VKTX $32.02
- Resistance Level
- TENB $35.57
- VKTX $34.60
- Average True Range (ATR)
- TENB 1.03
- VKTX 1.75
- MACD
- TENB -0.31
- VKTX -0.08
- Stochastic Oscillator
- TENB 14.37
- VKTX 43.33
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.